Episode 174 - February 27, 2026

What It Covers

Biotech Hangout Episode 174 examines the widening gap between FDA rhetoric on rare disease flexibility and actual agency decisions, covering Atara/Pierre Fabre's double CRL, Gilead's Arcellix acquisition, Novo Nordisk's cagrilintide failure against tirzepatide, and Xenon's upcoming phase three epilepsy readout with Adam Feuerstein.

Key Questions Answered

• •FDA Leadership Disconnect: When a new agency head like Vinay Prasad takes over CBER, prior agreements with review teams carry no binding obligation. Companies spanning two leadership regimes face the highest risk of surprise CRLs, as clinical deficiencies can emerge after manufacturing-only rejections with no prior warning from reviewer interactions.
• •Regulatory Signal vs. Action: Track what the FDA does, not what it says. Despite public messaging favoring rare disease acceleration and regulatory flexibility, industry is experiencing greater stringency. Prasad's twenty-year publication and video record signals a stringent regulatory philosophy that predates his FDA role and should be weighted heavily over official press statements.
• •CAR-T Acquisition Timing: Gilead's acquisition of Arcellix followed BLA acceptance for anito-cel, a BCMA CAR-T with a cleaner safety profile than carvykti. Deals structured around existing revenue-sharing agreements primarily shift the P&L middle rather than top-line economics, making BLA acceptance the key catalyst to watch before similar partnership-to-acquisition transitions occur.
• •GLP-1 Competitive Benchmarking: Cagrilintide failed non-inferiority against tirzepatide at week 84, posting roughly 23% weight loss versus 25.5% for tirzepatide, with worse tolerability signals. Novo's simultaneous 50% list price cut on Wegovy and Ozempic largely mirrors IRA-negotiated Medicare pricing, functioning as gross-to-net normalization rather than a genuine competitive pricing move.
• •Phase Three Endpoint Design: For Xenon's focal onset seizure trial X-TOLL 2, the primary endpoint is measured at twelve weeks versus eight weeks in the phase two X-TOLL study. Because anti-seizure medications show progressive efficacy gains through weeks nine through twelve, the longer averaging window dilutes early low-response weeks, potentially offsetting the typical phase two-to-three effect size decline.